Upgrade to Finviz Elite: Get our fastest platform speed, real-time data, and unlimited screening & charting. Start Free Trial

ABBV

Abbvie Inc

256.91

Jul 27 • 3:59 PM ET -2.45 (-0.94%)

257.82

Aftermarket • 7:59 PM ET +0.91 (0.35%)

Healthcare Drug Manufacturers - General USA Mega NYSE

Peers: LLY MRK PFE JNJ BMY AZN NVS AMGN NVO GILD

| Held by: VTI VOO IVV SPY VTV XLV VIG VYM VHT DGRO

Scroll to Statements

Index	S&P 500
Market Cap	453.91B
Enterprise Value	517.42B
Income	3.60B
Sales	62.82B
Book/sh	-3.77
Cash/sh	5.32
Dividend Est.	6.87 (2.67%)
Dividend TTM	6.83 (2.66%)
Dividend Ex-Date	Jul 15, 2026
Dividend Gr. 3/5Y	5.21% 6.56%
Payout	281.66%
Employees	57000
IPO	Dec 10, 2012

P/E	126.71
Forward P/E	15.61
PEG	0.71
P/S	7.23
P/B	-
P/C	48.33
P/FCF	22.72
EV/EBITDA	17.72
EV/Sales	8.24
Quick Ratio	0.68
Current Ratio	0.80
Debt/Eq	-
LT Debt/Eq	-
Option/Short	Yes / Yes

EPS (ttm)	2.03
EPS next Y	16.46
EPS next Q	3.60
EPS this Y	40.55%
EPS next Y	17.12%
EPS next 5Y	22.07%
EPS past 3/5Y	-29.11% -2.81%
Sales past 3/5Y	1.75% 5.95%
EPS Y/Y TTM	-13.63%
Sales Y/Y TTM	9.50%
EPS Q/Q	-46.38%
Sales Q/Q	12.43%
Earnings	Jul 31 BMO
EPS/Sales Surpr.	2.25% 1.93%

Insider Own	0.12%
Insider Trans	-2.14%
Inst Own	76.31%
Inst Trans	0.84%
ROA	2.64%
ROE	15221.82%
ROIC	6.21%
Gross Margin	70.58%
Oper. Margin	33.58%
Profit Margin	5.72%
SMA20	1.55%
SMA50	9.67%
SMA200	14.63%
Trades

Shs Outstand	1.77B
Shs Float	1.76B
Short Float	1.28%
Short Ratio	3.27
Short Interest	22.63M
52W High	261.64 -1.81%
52W Low	187.62 36.93%
Volatility	1.89% 2.42%
ATR (14)	5.90
RSI (14)	62.31
Beta	0.28
Rel Volume	0.78
Avg Volume	6.93M
Volume	5,404,822

Perf Week	1.39%
Perf Month	5.66%
Perf Quarter	29.29%
Perf Half Y	17.17%
Perf YTD	12.44%
Perf Year	35.02%
Perf 3Y	72.60%
Perf 5Y	117.79%
Perf 10Y	295.86%
Recom	1.66
Target Price	269.16
Prev Close	259.36
Price	256.91
Change	-0.94%

Date	Action	Analyst	Rating Change	Price Target Change
Apr-30-26	Upgrade	BofA Securities	Neutral → Buy	$234
Apr-21-26	Initiated	Canaccord Genuity	Buy	$262
Feb-25-26	Initiated	RBC Capital Mkts	Outperform	$260
Feb-20-26	Initiated	Barclays	Overweight	$275
Jan-08-26	Downgrade	Wolfe Research	Outperform → Peer Perform
Jan-07-26	Resumed	UBS	Neutral	$240
Dec-10-25	Upgrade	HSBC Securities	Hold → Buy	$265
Nov-13-25	Initiated	Scotiabank	Sector Outperform	$280
Nov-04-25	Downgrade	DZ Bank	Buy → Hold	$237
Oct-14-25	Downgrade	Erste Group	Buy → Hold
Oct-01-25	Downgrade	HSBC Securities	Buy → Hold
Sep-17-25	Upgrade	Berenberg	Hold → Buy	$270
Aug-12-25	Resumed	Piper Sandler	Overweight	$231
Aug-07-25	Upgrade	Daiwa Securities	Neutral → Outperform	$214
May-14-25	Downgrade	Citigroup	Buy → Neutral	$205
Apr-22-25	Initiated	Cantor Fitzgerald	Overweight	$210
Dec-10-24	Resumed	BofA Securities	Neutral	$191
Dec-05-24	Downgrade	Daiwa Securities	Outperform → Neutral	$180
Nov-22-24	Upgrade	Leerink Partners	Market Perform → Outperform	$206
Nov-15-24	Initiated	Wolfe Research	Outperform	$205

Show Previous Ratings

Jul-27-26 03:54PM	The Engine Behind ABBV Stock Has Real Parts (Trefis)
02:33PM	Collect 9.8% On LLY Stock Now, Own It 30% Cheaper If It Dips (Trefis)
06:16AM	Sarepta, in search of a turnaround, taps ex-AbbVie exec Severino as CEO (BioPharma Dive)
02:50AM	Johnson & Johnson Now Leads Its Pitch With An Oncology Bet (Trefis)
Jul-25-26 10:30AM	Johnson & Johnson Is Becoming A Narrower Company Than You Bought (Trefis)
06:44PM	Loading…
Jul-24-26 06:44PM	SpaceX Lands With a Thud (Barrons.com)
Jul-23-26 04:00PM	Genmab and AbbVie Provide Clarification on Phase 3 EPCORE DLBCL-1 Trial Evaluating Epcoritamab (DuoBody-CD3xCD20) in Patients with Relapsed/Refractory Diffuse Large B-cell Lymphoma (DLBCL) (Business Wire)
01:31PM	Best Monthly Dividend ETFs for Consistent Income (Kiplinger)
03:46AM	Missed AI, Memory Bull Run? Biotech May Be The Next Breakout Trade But Retail Sentiment Has Never Been Lower (Stocktwits)
Jul-22-26 09:17AM	LLY Has Momentum. The Question Is The Price (Trefis)
Jul-21-26 04:04PM	Eli Lilly Stock And The Price Of Confidence (Trefis)
02:31PM	AbbVie Stock Zigs When The Market Zags (Trefis)
01:46PM	Biotech IPOs Surge 55% as AI Listings Lose Momentum (GuruFocus.com)
08:35AM	Biotech IPO Gains Crush AI Listings With Standout 55% Return (Bloomberg)
12:00AM	Psychedelic drugs are going mainstream (Financial Times)
02:55PM	Loading…
Jul-20-26 02:55PM	Reading Between The Lines Of JNJ Stock's Latest Call (Trefis)
01:45PM	Eli Lilly Stock And The Price Of Confidence (Trefis)
02:00AM	What Comes After Merck's Keytruda? The Race for the Next Standard Cancer Treatment. (Barrons.com)
Jul-17-26 05:51PM	The Real Question Buried Inside Merck Stock's Premium Price (Trefis)
08:00AM	Allergan Aesthetics receives approval for Boey (trenibotulinumtoxinE), for use in Europe: the first and only rapid-onset, short-duration neurotoxin for the temporary improvement of frown lines in adult patients (PR Newswire)
Jul-16-26 09:19AM	What Could Push LLY Stock Higher From Here? (Trefis)
09:19AM	The Real Engine Behind Johnson & Johnson Stock's Next Climb (Trefis)
08:05AM	Why Abbott Earnings Are Sending the Stock Higher (Barrons.com)
Jul-14-26 03:00PM	The Race to Commercialize the Worlds Most Powerful Psychedelic (WSJ)
01:54PM	What Lilly's Peer-Beating Numbers Cost You (Trefis)
11:31AM	HCA Stock Plummets After Slashing 2026 Guidance Marks Fifth Straight Day Of Losses (Stocktwits)
08:05AM	SkinMedica Deepens Commitment to Regenerative Science with Continued Investment in Research and Development (PR Newswire)
08:00AM	Fresh off buyout, Akero execs reunite to advance long-acting psoriasis pill (BioPharma Dive)
Jul-13-26 09:12AM	How Does LLY Stock Reach $2,100? (Trefis)
Jul-10-26 04:16PM	Amazon, Microsoft and Meta Among HSBC Earnings Picks (GuruFocus.com)
08:02AM	Loading…
08:02AM	JNJ Stock Keeps Climbing. Should You Climb On? (Trefis)
Jul-09-26 10:58AM	Make Your AMGN Shares Pay You 8.7% While You Hold Them (Trefis)
09:13AM	ABBV Leads Its Peer Group. You Pay For That (Trefis)
08:16AM	One Formula, One Platform: Inside the Preclinical Milestone Behind Conexeu's Move Into Medical Aesthetics (PR Newswire)
07:35AM	The Billion-Dollar Pill: With NXP100, Nuvectis Pharma Just Staked Its Claim in the New Biotech Gold Rush (FinanceWire)
02:19AM	FTSE 100 Live: AstraZeneca drags while Computacenter soars, US AI stocks gain (Proactive)
12:38AM	SLS Stock Snaps 2-Day Slide: Sellas SLS009 AML Trial Spotlights Big Pharma Drug Combo From ABBV, RHHBY And BMY (Stocktwits)
Jul-08-26 11:36AM	The Wide Divide Ahead For Eli Lilly Stock (Trefis)
Jul-07-26 09:45AM	A $190 Billion Weight-Loss Boom Exposed a Tissue-Restoration Gap, and One Nasdaq Company Is Moving to Fill It (PR Newswire)
06:06AM	EC approves AbbVie's Tepkinly combination for follicular lymphoma (Pharmaceutical Business Review)
04:42AM	Can anyone catch up to Eli Lilly? (Pharma Voice)
Jul-06-26 04:23PM	What Eli Lilly Stock Said When It Had Too Much Business (Trefis)
01:45PM	AbbVie Announces TEPKINLY (epcoritamab) in Combination with Lenalidomide and Rituximab is Approved by the European Commission for the Treatment of Relapsed or Refractory Follicular Lymphoma (PR Newswire)
Jul-02-26 01:29PM	JNJ Stock Management Sees A Breakout, The Market Sees A Standoff (Trefis)
05:29AM	Can pharma sustain its $2T trajectory? (Pharma Voice)
Jun-30-26 04:24PM	Why Is JNJ Stock Defying The Markets Daily Mood Swings? (Trefis)
04:10PM	US House committee opens investigation into Merck, AbbVie China drug trials (Reuters)
12:19PM	Merck, AbbVie probed by US lawmakers over China clinical trials: report (Proactive)
08:55AM	Merck, AbbVie investigated over China military hospital drug trials (Quartz)
05:35AM	Genmab Shares Climb After Lymphoma Therapy Hits Goal in Trial (The Wall Street Journal)
Jun-29-26 04:15PM	AbbVie Announces Positive Phase 3 Results for Epcoritamab Plus Lenalidomide in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma (PR Newswire)
02:33PM	AbbVie Stock Rockets 17% With 5-Day Winning Streak (Trefis)
01:37PM	Should You Chase The Breakout In Eli Lilly Stock? (Trefis)
03:10AM	AbbVie Receives Positive CHMP Opinion for Upadacitinib (RINVOQ) for the Treatment of Adults and Adolescents with Severe Alopecia Areata (PR Newswire)
03:00AM	AbbVie Receives Positive CHMP Opinion for Upadacitinib (RINVOQ) for the Treatment of Adults and Adolescents with Non-segmental Vitiligo (PR Newswire)
Jun-26-26 04:50PM	SKYRIZI (risankizumab-rzaa) Now FDA Approved for Pediatric Use in Psoriatic Disease (PR Newswire)
02:39PM	Healthcare stocks have become a haven for investors ditching tech (MarketWatch)
01:49PM	Lilly, J&J and AbbVie Hit New Highs (GuruFocus.com)
12:03PM	AbbVie Stock's Growth Story Has One Question Mark (Trefis)
08:00AM	AbbVie to Host Second-Quarter 2026 Earnings Conference Call (PR Newswire)
Jun-24-26 03:32PM	The Number That Could Test AbbVie Stock (Trefis)
02:15PM	VERAXA Biotech Expands R&D Hub in Heidelberg as Programs Advance Towards Clinical Development (Exec Edge)
08:00AM	BOTOX Cosmetic (onabotulinumtoxinA) Introduces The Confidence Collective's Entrepreneur Class of 2026 (PR Newswire)
Jun-23-26 06:36PM	Thinking Thin Pays Off: Lilly To Dominate Pharma World By 2032 (MediaPost)
03:57PM	The $50B Plan Merck Stock Was Broadcasting (Trefis)
08:45AM	AbbVie Secures EU Approval for Skyrizi in Pediatric Plaque Psoriasis (ABBV) (InvestorsHub)
08:20AM	Should You Buy Or Sell AbbVie Stock At $230? (Trefis)
08:00AM	Allergan Aesthetics receives approval for Boey (trenibotulinumtoxinE) in Canada, the first and only rapid-onset, short-duration neurotoxin for the temporary improvement of frown lines in adult patients (PR Newswire)
05:00AM	AbbVie Announces European Commission Approval of MAVIRET (Glecaprevir/Pibrentasvir) for People with Acute Hepatitis C Virus Infection (PR Newswire)
03:00AM	AbbVie Announces European Commission Approval of SKYRIZI (risankizumab) for the Treatment of Pediatric Patients with Moderate to Severe Plaque Psoriasis (PR Newswire)
Jun-22-26 11:04PM	Why Did INTC, KEEL, APGE Stocks Hit 52-Week Highs Today? (Stocktwits) +6.25%
04:08PM	AbbVie Goes On The Offensive With $10.9 Billion Takeover (Investor's Business Daily)
03:47PM	Abbvie acquiring Apogee for $10.9B, Coca-Cola vs. IRS in appeals court (Yahoo Finance Video)
02:59PM	AbbVie's $10.9 Billion Apogee Deal Joins a $200 Billion Pharma Spree (GuruFocus.com)
11:40AM	Prolium Bioscience Sclerosis, Lupus Treatment Studies Advancing (Exec Edge)
11:33AM	AbbVie deepens immunology legacy in $10.9bn Apogee buyout (Pharmaceutical Technology)
11:12AM	AbbVie's Deal with Apogee; Regenxbio Moves on Gene Therapy Drug \| Stock Movers (Bloomberg)
10:46AM	Merck Stocks New Drugs Were Already Answering The Big Question (Trefis)
10:04AM	AbbVie to acquire Apogee Therapeutics in $10.9B deal (Proactive)
09:08AM	Apogee Therapeutics, BitFuFu rise premarket; AbbVie gains after deal (Investing.com)
09:08AM	Why AbbVie Is Spending $11 Billion to Buy Apogee Therapeutics (Barrons.com)
08:58AM	AbbVie Strikes $10.9 Billion Deal for Apogee to Strengthen Future Immunology Portfolio (ABBV) (InvestorsHub)
08:46AM	Dow Jones opens higher but Nasdaq flat as hawkish Fed still looms (Proactive)
08:32AM	AbbVie acquires Apogee Therapeutics for $10.9 billion (Quartz)
08:32AM	AbbVie is buying an eczema and asthma drug developer for nearly $11 billion (Quartz)
08:08AM	5 Things to Know Before the Stock Market Opens (Investopedia)
07:42AM	AbbVie to Buy Apogee Therapeutics for $10.9 Billion in Cash (The Wall Street Journal)
07:06AM	Apogee Therapeutics Stock Soars. It's Being Bought by AbbVie for $10.9 Billion. (Barrons.com)
07:00AM	AbbVie to Acquire Apogee Therapeutics, Deepening Immunology Portfolio (PR Newswire)
Jun-20-26 12:11PM	AbbVie would gain an experimental eczema drug by buying biotech: report (MarketWatch)
Jun-19-26 04:09PM	Stocks Stall as Iran Nuclear Talks Hit Early Snag: Markets Wrap (Bloomberg)
Jun-18-26 08:56PM	How One Partnership Profit Line Reframes The Regeneron Pharmaceuticals Stock Story (Trefis) +6.25%
04:57PM	What If Amgen Stock's Patent Worries Are Hiding Its Real Growth Engine? (Trefis)
04:05PM	AbbVie Declares Quarterly Dividend (PR Newswire)
Jun-17-26 02:21PM	Eli Lilly Stock's Trillion-Dollar Question (Trefis)
01:08PM	The Number That Could Test Johnson & Johnson Stock (Trefis)
11:57AM	Everyone Is Watching Eli Lilly Stock's New Drugs. Here Is the Metric That Vanished (Trefis)
Jun-16-26 08:15AM	Fresh Off Its Nasdaq Debut, a Regenerative-Medicine Upstart Is Stacking Its Board With Big-Pharma Firepower (PR Newswire)
08:00AM	Allergan Aesthetics Receives U.S. FDA Approval for SKINVIVE by JUVEDERM for the Improvement of Neck Appearance (PR Newswire)
Jun-12-26 04:53PM	What Could Push JNJ Stock Higher From Here? (Trefis)

AbbVie, Inc. is a research-based biopharmaceutical company, which engages in the development and sale of pharmaceutical products. It focuses on treating conditions such as chronic autoimmune diseases in rheumatology, gastroenterology, and dermatology, oncology, including blood cancers, virology, including hepatitis C virus (HCV) and human immunodeficiency virus (HIV), neurological disorders such as Parkinson's disease, metabolic disorders, including thyroid disease and complications associated with cystic fibrosis, pain associated with endometriosis, and other serious health conditions. The company was founded on October 19, 2011 and is headquartered in North Chicago, IL.

CEO & Chairman of the BoardMr. Robert A. Michael CPA

Executive VP & CFOMr. Scott T. Reents

Executive VP & COODr. Azita Saleki-Gerhardt Ph.D.

Executive VP of Research & Development and Chief Scientific OfficerDr. Roopal B. Thakkar M.D.

Executive VP & Chief Commercial OfficerMr. Jeffrey Ryan Stewart

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
ROBERT J ALPERN	Director	May 26 '26	Proposed Sale	214.00	13,000	2,781,991		May 26 04:10 PM
Purdue David Ryan	SVP, Controller	Mar 04 '26	Sale	233.56	5,230	1,221,519	2,654	Mar 06 05:05 PM
David R. Purdue	Officer	Mar 04 '26	Proposed Sale	233.56	5,230	1,221,519		Mar 06 05:04 PM
Siatis Perry C	EVP, GC AND SECRETARY	Mar 02 '26	Sale	234.39	18,668	4,375,549	4,619	Mar 03 06:10 PM
PERRY C SIATIS	Officer	Mar 02 '26	Proposed Sale	234.39	18,668	4,375,585		Mar 02 04:05 PM
Siatis Perry C	EVP, GC AND SECRETARY	Feb 25 '26	Option Exercise	172.62	22,381	3,863,458	60,518	Feb 27 05:00 PM
Siatis Perry C	EVP, GC AND SECRETARY	Feb 25 '26	Sale	230.00	22,381	5,147,630	38,137	Feb 27 05:00 PM
PERRY C SIATIS	Officer	Feb 25 '26	Proposed Sale	230.00	22,381	5,147,630		Feb 25 04:49 PM
Richard A. Gonzalez	Former Director	Aug 22 '25	Proposed Sale	210.84	62,755	13,231,264		Aug 22 06:02 PM
Richard A. Gonzalez	Former Director	Aug 21 '25	Proposed Sale	211.04	90,000	18,993,948		Aug 21 06:04 PM
SALEKI-GERHARDT AZITA	EVP, CHIEF OPERATIONS OFFICER	Aug 12 '25	Option Exercise	54.86	42,370	2,324,418	219,662	Aug 14 05:00 PM
SALEKI-GERHARDT AZITA	EVP, CHIEF OPERATIONS OFFICER	Aug 12 '25	Sale	198.42	42,370	8,407,055	177,292	Aug 14 05:00 PM
AZITA SALEKI-GERHARDT	Officer	Aug 12 '25	Proposed Sale	198.42	42,370	8,407,068		Aug 12 07:22 PM
Richard A. Gonzalez	Former Director	Aug 01 '25	Proposed Sale	195.83	61,500	12,043,268		Aug 08 05:03 PM
Donoghoe Nicholas	EVP, CHIEF BUS/STRAT OFFICER	Aug 05 '25	Sale	198.51	13,295	2,639,253	58,247	Aug 07 05:00 PM
NICHOLAS DONOGHOE	Officer	Aug 05 '25	Proposed Sale	198.51	13,299	2,639,966		Aug 05 04:40 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

ABBV

Abbvie Inc

Upgrade your Finviz experience